Identification of 17 novel epigenetic biomarkers associated with anxiety disorders using differential methylation analysis followed by machine learning-based validation
Authors:
Open Access
- 17 February 2025
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 17 (1) , 1-13
Abstract
The changes in DNA methylation patterns may reflect both physical and mental well-being, the latter being a relatively unexplored avenue in terms of clinical utility for psychiatric disorders. In this study, our objective was to identify the methylation-based biomarkers for anxiety disorders and subsequently validate their reliability. A comparative differential methylation analysis was performed on whole blood samples from 94 anxiety disorder patients and 296 control samples using targeted bisulfite sequencing. Subsequent validation of identified biomarkers employed an artificial intelligence-based risk prediction models: a linear calculation-based methylation risk score model and two tree-based machine learning models: Random Forest and XGBoost. Seventeen novel epigenetic methylation biomarkers were identified to be associated with anxiety disorders. These biomarkers were predominantly localized near CpG islands, and they were associated with two distinct biological processes: 1) cell apoptosis and mitochondrial dysfunction and 2) the regulation of neurosignaling. We further developed a robust diagnostic risk prediction system to classify anxiety disorders from healthy controls using the 17 biomarkers. Machine learning validation confirmed the robustness of our biomarker set, with XGBoost as the best-performing algorithm, an area under the curve of 0.876. Our findings support the potential of blood liquid biopsy in enhancing the clinical utility of anxiety disorder diagnostics. This unique set of epigenetic biomarkers holds the potential for early diagnosis, prediction of treatment efficacy, continuous monitoring, health screening, and the delivery of personalized therapeutic interventions for individuals affected by anxiety disorders.Keywords
All Related Versions
Funding Information
- Ministry of SMEs and Startups (1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425157253, 1425156792, 1425156792, 1425157253)
- Ministry of Trade, Industry and Energy (1415170577, 1415170577, 1415170577, 1415170577, 1415170577, 1415170577, 1415170577, 1415187694, 1415187694, 1415187694, 1415187694, 1415187694, 1415170577)
- Ulsan National Institute of Science and Technology (1.200108.01, 1.200108.01, 1.200108.01, 1.200108.01, 1.200108.01, 1.200108.01, 1.200108.01)
This publication has 88 references indexed in Scilit:
- Ultrafast one‐pass FASTQ data preprocessing, quality control, and deduplication using fastpiMeta, 2023
- miR‐3146 induces neutrophil extracellular traps to aggravate gout flareJournal of Clinical Laboratory Analysis, 2021
- Serotonin and its metabolites reduce oxidative stress in murine RAW264.7 macrophages and prevent inflammationJournal of Physiology and Biochemistry, 2020
- Toward understanding the origin and evolution of cellular organismsProtein Science, 2019
- LncRNA F11‐AS1 suppresses liver hepatocellular carcinoma progression by competitively binding with miR‐3146 to regulate PTEN expressionJournal of Cellular Biochemistry, 2019
- DNA methylation-based variation between human populationsMolecular Genetics and Genomics, 2016
- Role of GABA in anxiety and depressionDepression and Anxiety, 2006
- The Structure of Genetic and Environmental Risk Factors for Anxiety Disorders in Men and WomenArchives of General Psychiatry, 2005
- Structure, function and evolution of CpG island promotersCellular and Molecular Life Sciences, 2003
- Role of the Serotonin Transporter Promoter Polymorphism in Anxiety-Related TraitsArchives of General Psychiatry, 1998